An overview on d-amino acids
G Genchi - Amino acids, 2017 - Springer
More than half a century ago researchers thought that d-amino acids had a minor function
compared to l-enantiomers in biological processes. Many evidences have shown that d …
compared to l-enantiomers in biological processes. Many evidences have shown that d …
Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
M Carbon, CU Correll - CNS spectrums, 2014 - cambridge.org
Since currently available antipsychotic medications predominantly treat hallucinations,
delusions, disorganized thoughts and behavior, and related agitation/aggression, attention …
delusions, disorganized thoughts and behavior, and related agitation/aggression, attention …
[HTML][HTML] Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
MJ Millan, K Fone, T Steckler, WP Horan - European …, 2014 - Elsevier
Schizophrenia is a complex and multifactorial disorder generally diagnosed in young adults
at the time of the first psychotic episode of delusions and hallucinations. These positive …
at the time of the first psychotic episode of delusions and hallucinations. These positive …
The NMDA receptor as a target for cognitive enhancement
GL Collingridge, A Volianskis, N Bannister, G France… - …, 2013 - Elsevier
NMDA receptors (NMDARs) play an important role in neural plasticity including long-term
potentiation and long-term depression, which are likely to explain their importance for …
potentiation and long-term depression, which are likely to explain their importance for …
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Severe psychiatric disorders such as schizophrenia are related to cognitive and negative
symptoms, which often are resistant to current treatment approaches. The glutamatergic …
symptoms, which often are resistant to current treatment approaches. The glutamatergic …
D-Serine: potential therapeutic agent and/or biomarker in schizophrenia and depression?
MAB MacKay, M Kravtsenyuk, R Thomas… - Frontiers in …, 2019 - frontiersin.org
D-Serine is a potent co-agonist at the NMDA glutamate receptor and has been the object of
many preclinical studies to ascertain the nature of its metabolism, its regional and cellular …
many preclinical studies to ascertain the nature of its metabolism, its regional and cellular …
Involvement of cholinergic, adrenergic, and glutamatergic network modulation with cognitive dysfunction in Alzheimer's disease
Alzheimer's disease (AD), the most common cause of dementia, is a progressive
neurodegenerative disease. The number of AD cases has been rapidly growing worldwide …
neurodegenerative disease. The number of AD cases has been rapidly growing worldwide …
d-AMINO ACIDS IN ANIMAL PEPTIDES
G Kreil - Annual review of biochemistry, 1997 - annualreviews.org
d-amino acids have been detected in a variety of peptides synthesized by animal cells.
These include opiate and antimicrobial peptides from amphibian skin, neuropeptides from …
These include opiate and antimicrobial peptides from amphibian skin, neuropeptides from …
Glutamatergic transmission in schizophrenia: from basic research to clinical practice
J Kantrowitz, DC Javitt - Current opinion in psychiatry, 2012 - journals.lww.com
Glutamatergic transmission in schizophrenia: from basic rese... : Current Opinion in Psychiatry
Glutamatergic transmission in schizophrenia: from basic research to clinical practice : Current …
Glutamatergic transmission in schizophrenia: from basic research to clinical practice : Current …
Targeting of NMDA receptors in new treatments for schizophrenia
K Hashimoto - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
Introduction: Abnormalities in glutamatergic neurotransmission mediated by N-methyl-d-
aspartate (NMDA) are implicated in the pathophysiology of schizophrenia, although the …
aspartate (NMDA) are implicated in the pathophysiology of schizophrenia, although the …